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INTRODUCTION
Clostridium difficile is one of the colonic 
microfloras which can be categorised as 
opportunistic pathogen, obligate anaerobe, 
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ABSTRACT
Clostridium difficile can cause severe diseases with significant morbidity and mortality in infected patients. 
The rate of Clostridium difficile infection is high in North America and European countries. Metronidazole 
and vancomycin have been recommended as the treatments of choice since 1990s. Recurrent infection 
due to Clostridium difficile is common after several days of antibiotic administration. Probiotics have 
been used in these patients as an adjunct treatment with some successful findings. However, a detailed 
investigation on the use of probiotic for infected patients is still needed, particularly for its real efficacy.
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Gram-positive and spore-forming bacterium 
(Bruno et  al . ,  2006;  Pi tuch,  2009) . 
Approximately 3% of C. difficile tends to be 
found in intestines of healthy adults and 40% 
in neonates (Libby et al., 2009).
In 1978, C. difficile was identified as 
one of the opportunistic pathogens to have 
caused diarrhoea (Huang et al., 2009). It 
was reported that this bacterium responsible 
for 10-25% antibiotic-associated diarrhoea, 
50-75% antibiotic-associated colitis and 
90-100% cases of antibiotic-associated 
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pseudomembranous colitis, respectively (McMaster-Baxter et al., 2007).
C. difficile produces two main toxins, namely, enterotoxin A (TcdA) and cytotoxin B 
(TcdB) (Pituch, 2009). These toxins are among the virulent factors that are responsible for the 
pathogenesis of antibiotic-associated diarrhoea and pseudomembranous colitis (Pituch, 2009).
 The bacteria can be further classified as non-toxigenic strains [A-B-] (not producing both 
toxins), toxigenic strains [A+B+] (i.e. producing both toxins), and [A-B+] strains (producing 
only toxin TcdB) (Rupnik et al., 2003). In addition, C. difficile also produces toxin called 
binary toxin CDT. This toxin is composed of two non-linked components: CDTa (enzymatic 
component) and CDTb (binding component) (Rupnik et al., 2003). However, the pathogenicity 
for this toxin is still unknown (Rupnik et al., 2003).
EPIDEMIOLOGY
Prior to 2001, epidemiological information was limited due to mild manifestation and 
inexpensive treatment of C. difficile infection [CDI] (Oughton et al., 2008). After 2001, 
however, the incidences of Clostridium difficile-associated diarrhoea [CDAD] had increased 
drastically to 26% in U.S. hospitals (Miller et al., 2006). A study by Walbrown et al. (2008) 
in North America showed more than 250,000 cases of CDAD in European countries, and the 
experience of CDI was almost similar in North America (Oughton et al., 2008; Denève et 
al., 2009). The information about C. difficile and CDAD was also limited in Asian countries 
(Oughton et al., 2008). For instance in Japan, the epidemiology of CDAD has not been well 
documented (Sawabe et al., 2007). In Malaysia, data on CDI is rather limited. The only 
documented data that could be traced was published by Parasakthi et al. (1988) who reported 
seven cases of CDAD.
CDAD does not only affect adults but it can also have few impacts on infants and neonates. 
It has been reported that 26.6 - 43.5% of neonates and infants in Europe and USA are carriers 
of C. difficile (Pituch, 2009). In Japan, the carrier rates for C. difficile were 84.4% and 30.3% 
in infants under 2 years old were 84.4% and 30.3% for children more than 2 year old (Pituch, 
2009).
There are several C. difficile strains that can cause CDI. For instance, C. difficile strain 
027 causes severe colitis, higher mortality and higher recurrent rates (CA Clements et al., 
2010; Dawson et al., 2009). This strain can produce higher levels of TcdA and TcdB (Denève 
et al., 2009). In UK, strain 027 has increased from 25.9% to 41.3% and the increase pattern 
was similar to that in Canada where it reached 75.2% by the year 2003. In Japan, strain 027 
infection was documented in a hospitalized patient in 2005 (Oughton et al., 2008). This strain 
was first detected in several cases reported from in Western Australia, South Korea, Hong Kong 
and Costa Rica were reported between 2008 and 2010 (Clements et al., 2010). Moreover in 
Japan, the most common strain that was responsible for causing outbreaks in several hospitals 
was PCR ribotype smz (Sawabe et al., 2007). This PCR ribotype smz has been identified from 
the analysis of 148 isolates in a Japanese teaching hospital (Oughton et al., 2008).
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IMMUNE RESPONSE TO CDI
Patients with C. difficile diarrhoea have decreased amount of serum IgG antitoxin A (Wilcox, 
2003). This antibody is important to reduce the severity of symptoms and reduce the rate of 
recurrent diarrhoea (McMaster-Baxter et al., 2007).
Several studies have examined the success developmental rate of immune response towards 
C. difficile toxins in recurrent CDAD (RCDAD) patients. Huebner et al. (2006) demonstrated 
that when intravenous immunoglobulin (IVIG) was given to five children who had RCDAD, 
their IgG antitoxin A levels were increased. Meanwhile, when IVIG was administered to five 
adult RCDAD patients, three of them had no further recurrence with one had a recurrence 
while one had died of uncontrolled CDAD (Huebner et al., 2006).
Orally administered antibodies have been used for humans but their effectiveness is still 
inconclusive. Whey protein concentrate from the milk of C. difficile-immunised cows contains 
high level of IgA antibodies. It is safe and is able to decrease the recurrence rates up to 50% 
(Bauer et al., 2009a). However in another study, nine out of 16 CDAD patients developed 
RCDAD when it was given to them (Huebner et al., 2006).
Immunoglobulins from the colostrums of cows immunised with C. difficle toxoids were 
used to neutralize the effects of toxins A and B in-vitro and had been shown to inhibit the 
enterotoxic effects in a hamster CDI model (Huebner et al., 2006; Bauer et al., 2009a). In 
addition, anti-toxin A antibodies and anti-toxin B antibodies were also found to inhibit the 
effects of CDAD although the mechanism of immune response to toxin B has not been well 
understood (Mylonakis et al., 2001).
Clostridium difficile ASSOCIATED DIARRHOEA (CDAD) AND 
PSEUDOMEMBRANOUS COLITIS  
CDAD and pseudomembranous colitis are among the common diseases caused by CDI in 
hospitalized patients. The incidence and severity of CDAD have been shown to be increased in 
many studies. In the United States, for instance, this disease was identified as a major cause for 
hospital-acquired diarrhoea, especially among patients in long-term care facilities. The disease 
was also seen among patients aged 65 years and above (McCusker et al., 2003; Mylonakis et 
al., 2001; Pelleschi, 2008).
Usually, the colonic microflora of healthy adults is resistant to C. difficile colonization 
(Poutanen et al., 2004). However, the protection conferred by the colonic microflora will 
decrease when patients are treated with antibiotics. This causes an increase in the number of 
C. difficile in the colon, which may lead to severe diarrhoea or pseudomembranous colitis 
(McMaster-Baxter et al., 2007; Pelleschi, 2008).
The aetiology for CDAD is believed due to the release of to be toxins A and B (Pelleschi, 
2008). When the spores enter the colon, C. difficile will proliferate and release toxins A 
and B (Miller et al., 2006). Once the toxins are secreted, toxin A will activate macrophages 
and mast cells and subsequently the inflammatory mediators will be released. Activation 
of these cells causes disruption of the cell wall junction, resulting in an increase in the 
permeability of the intestinal wall and subsequently diarrhoea. Meanwhile, toxin B degrades 
the epithelial cells in colon (Pelleschi, 2008). In addition, production of hydrolytic enzymes 
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leads to pseudomembranous colitis and watery bloody diarrhoea (Miller et al., 2006). 
Pseudomembranous colitis is a term used for severe CDI (Wilcox, 2003). Most patients will 
present with severe diarrhoea. It usually occurs within 1-2 weeks after the commencement of 
broad-spectrum antibiotics (Huebner et al., 2006).
SIGNS AND SYMPTOMS OF CDAD AND PSEUDOMEMBRANOUS COLITIS
The clinical manifestations of CDAD range from mild to severe symptoms which include 
malaise, lower abdominal cramps, nausea, vomiting, fever, loss of appetite and leukocytosis 
(Miller et al., 2006; Koo, 2008; Mylonakis et al., 2001). The symptoms of CDAD may appear 
on the first day or up to 6 weeks of the antibiotic therapy (Mylonakis et al., 2001). The stool 
can become watery, voluminous and non-bloody (McMaster-Baxter et al., 2007). As for 
pseudomembranous colitis, the common signs and symptoms are painful abdominal distension, 
watery diarrhoea, fever, and colonic bleeding (Tsourous et al., 2007; Mylonakis et al., 2001).
DIAGNOSIS
Currently, CDI can be diagnosed either by laboratory methods or endoscopy (Wilcox, 2003). 
In laboratory diagnosis, the bacterium is isolated and cultured but this method is very time 
consuming. However, epidemiology of C.difficile strains in a ward or hospital is determined 
by using this method.
The detection of the toxin B cytotoxicity can be performed by using tissue culture assay 
(Mylonakis et al., 2001). This test is the most sensitive (94%-100%) and specific (99%) for 
diagnosing CDI but it takes approximately 1 to 3 days (Mylonakis et al., 2001). The most 
frequently used method to detect the toxins of C. difficile is by ELISA test kit, which is easy to 
perform but it has low level of sensitivity (Wilcox, 2003; Mylonakis et al., 2001). Immunoassays 
are known to be the best method to perform cell cytotoxicity assay with sensitivity and 
specificity in the range of 85-95%. Toxins tcdA, tcdB, cdtA and cdtB can also be detected by 
using real-time polymerase chain reaction (RT-PCR) (Huang et al., 2009).
Diagnosis by sigmoidoscopy remains as the optimum way of distinguishing different 
pathological conditions in the large intestine. Common sigmoidoscopic findings are yellow 
adherent plaques measuring 2-10 mm in diameter, which are formed by pseudomembranes 
that are found scattered over the colonic mucosa and interspersed with hyperemic mucosa 
(Bonasera et al., 2004).
ANTIBIOTIC SUSCEPTIBILITY
Currently, antimicrobial therapy is the mainstay of treatment for CDI (Huang et al., 2009). 
Many studies have shown the use of metronidazole and vancomycin as the primary treatment 
for CDI as they are the most active agents in vitro, with narrow MIC50 and MIC90 ranges (Huang 
et al., 2008). Metronidazole commonly acts as the first line treatment, while vancomycin is 
normally used for the second line therapy (Johnson, 2009).
Fluoroquinolones and rifaximin have also been used in CDI treatment (Johnson et al., 2007; 
McCusker et al., 2003). Cases of fluoroquinolones-resistant C. difficile have been reported 
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in CDI (Huang et al., 2009). For example, 37.5%, 46.4%, 12% and 7% of C. difficile isolates 
have been reported to be resistant to moxifloxacin in European countries, Shanghai, Germany 
and France, respectively (Huang et al., 2009). Of interesting note, the use of fluoroquinolones 
has been documented as one of the main risk factors for CDAD (Miller et al., 2006; McCusker 
et al., 2003).
Rifaximin is commonly used for the treatment of patients with traveller’s diarrhea. 
However, this antibiotic can also be used to treat CDI as well. A study had reported that eight 
patients who had multiple RCDAD responded to rifaximin, except for one person who needed 
a second administration of rifaximin for complete resolution (Johnson, 2009).
Broad-spectrum antibiotics such as penicillins, cephalosporins and clindamycin can 
contribute to the changes of colonic microflora and cause the continuation of CDAD (Surawicz, 
2003; Poutanen et al., 2004). In addition, the administration of meropenem and piperacillin 
or tazobactam may have an effect on other gut flora and probably increase the risk of CDI 
(Huang et al., 2008).
Giving antibiotics to all CDI patients is not a routine practice. This is because some patients 
will recover spontaneously from the disease but this happens mainly in mild cases of CDI. Thirty 
three percent of mild CDI patients had spontaneous recovery (Bauer et al., 2009b). Meanwhile, 
other studies showed that once the antibiotics were discontinued, 15-23% of CDAD patients 
had spontaneous recovery (McMaster-Baxter et al., 2007). However, there were possibilities 
that the recurrence would be increased if patients took another antibiotic for the second time 
after discontinuing the first antibiotic (Bauer et al., 2009b).
One of the problems of antibiotic usage is resistance. There were reports showing 7.7% 
and 6.3% cases of antibiotic resistance towards metronidazole in Spain in 1994 and 2002, 
respectively. There was a drastic increase from 20% to 47.2% in Canada, and this occurred 
after the patients had received metronidazole (Miller et al., 2006).
There was also resistance to vancomycin and this has been increased every year (Huang 
et al., 2009). For example in Scotland, it has been reported that the increase of vancomycin 
resistance was from 2.7% (1999-2000) to 21.6% (2005) (Huang et al., 2009). According to 
McMaster-Baxter et al. (2007), 3% of C. difficile isolates had intermediate level of resistance 
towards vancomycin; however the clinical implication of this finding was not studied.
RECURRENCES OF CDI AND PROBIOTIC
Recurrent CDI has seldom encountered in hospitalized patients. This usually occurs in 20-35% 
of the patients post 5-8 days of antibiotic therapy (Huebner et al., 2006). It had been stated that 
the recurrence could probably be due to the decrease in the colonisation resistance (Johnson, 
2009). Apart from the use of antibiotics, other known risk factors for CDI recurrence are as 
follows: low level of immunization (anti-toxin IgM and IgG), older age, female sex and renal 
disease (Johnson, 2009; Huebner et al., 2006).
As an alternative, probiotics have been used as an adjunct treatment for CDI. Probiotics 
are living microorganisms which can provide benefits to the host (Miller, 2009). Commonly 
used probiotics are Lactobacillus species and Bifidobacteria species. They are available either 
in yogurt or food supplements. Probiotics are also found in the human colon. Approximately 
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102-106 of Lactobacillus species and 108-1012 of Bifidobacterium species form parts of the 
intestinal flora. However, the composition of the probiotics in the colon will decrease as the 
subjects get older (Salminen et al., 2004).
Probiotics should be taken after the administration of antibiotics. Usually, the effect of 
probiotics will be seen over certain time duration. According to several studies, probiotics 
recipients had a remarkable reduction in recurrences when these were administered to them 
for 21 to 38 days (Huebner et al., 2006).
Clinical evidence has supported the use of probiotics for the treatment of gastrointestinal 
infections, inflammatory bowel diseases and cancer (Saarela et al., 2000). Now, many scientists 
believe that the use of probiotic can prevent exacerbation of CDI. For instance, S. boulardii 
has successfully reduced CDI occurrence. On the other hand, L. rhamnosus GG has shown 
mixed results in CDAD prevention (Graul et al., 2009; Lawrence et al., 2005).
According to Gerding et al. (2008) and Miller (2009), the most effective way to 
prevent recurrences is by combining S. boulardii with a standard therapy (metronidazole or 
vancomycin). In their reports, 11 out of 13 patients with multiple recurrences of CDI had no 
further recurrences. Another study has shown that the rate of RCDAD in 60 patients decreased 
to 50% after combining S. boulardii with the standard therapy (Huebner et al., 2006). The 
high dose of vancomycin, with S. boulardii, had reduced the recurrence of CDI; however, this 
would not be effective if the low dose of standard therapy was prescribed with or without the 
combination with S. boulardii (Gerding et al., 2008).
The combination of Lactobacillus plantarum 299v with metronidazole had also been used 
in several studies. Unfortunately, this combination did not yield good results since recurrences 
occurred in four out of eleven patients, as compared to six out of nine patients who had received 
only metronidazole and placebo (Huebner et al., 2006).
Studies in Valley Lutheran Medical Centre and Mesa Lutheran Hospital have demonstrated 
the effectiveness of combining Lactobacillus species and Bifidobacterium species on CDAD. 
In particular, the results showed that CDAD in the year 1999, 2000 and 2001 had decreased 
to 66%. This finding indicates that the combination of probiotics with antibiotic therapy could 
be helpful in decreasing CDAD (Graul et al., 2009). 
There are varying opinions against the use of probiotics as an adjunct therapy. It has been 
reported that probiotics are not effective in treating C. difficile and in fact may be harmful 
to human. Gerding et al. (2008) claimed that the current literature did not support the use of 
probiotics for CDI. It has been reported that Lactobacillus may cause bacteraemia whereas 
S. boulardii may cause fungemia in both immunocompetent and immunocompromised hosts 
(Gerding et al., 2008; Miller, 2009).
OTHER ALTERNATIVE TREATMENTS
Other novel alternative treatments for CDI have also been developed. A study on vaccine was 
conducted among healthy volunteers. The parenteral vaccine that inactivates toxins A and B 
demonstrated an increase in antibody levels. A combination of vaccine with vancomycin in 
three patients with multiple episodes of RCDAD showed no further recurrences (Huebner et 
al., 2006).
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Faecal transplant is another innovative novel treatment. This approach has been used 
among patients who experienced CDI recurrence. A study was carried out among 18 patients 
who had suffered from recurrent C. difficile colitis. Their stools were treated with vancomycin 
hydrochloric tablet (250mg) and omeprazole capsules (20mg) for four days prior to the 
transplant procedure. Nasogastric tube was used to transfer the faeces obtained from healthy 
donors to these patients. As a result, 16 out of 18 did not experience any recurrence after the 
treatment (Aas et al., 2003).
A randomized trial using faecal transplant was done in the Netherland. In that study, 
vancomycin was given to patients with recurrent CDI. In order to reduce C. difficile load, 
gastrointestinal lavage was performed using Kleanprep [macrogol]. The donor faeces were 
then transferred to the patients through a nasoduodenal tube (Bauer et al., 2009a). Johnson 
(2009) showed that by using faecal transplant, 90% of 67 patients had reduced number of 
CDI recurrence.
Another alternative treatment that has been explored was tolevamer. Tolevamer is a polymer 
that has been tested in hamster CDI model and shown to be highly effective for C. difficle toxins. 
However, the use of this particular polymer in human needs further study (Bauer et al., 2009a).
CONCLUSION
C. difficle is a type of bacterium that causes a spectrum of diseases in human. The most 
challenging part in the CDI treatment is the recurrence cases of C. difficile and the high chances 
for patients to develop CDI recurrence. Metronidazole-resistant C. difficile is also need to be 
considered during the treatment. Thus, re-evaluating the use of metronidazole as the first-line 
treatment is needed in areas with high resistant rates. In addition, alternative ways should be 
explored to overcome this problem.
Probiotics have been shown to give some promising results in treating CDI patients. 
However, the use of probiotics as an adjunct treatment for CDI needs further investigations. In 
particular, the safety aspect and quality control of probiotics should be emphasized especially 
in immunocompromised patients. There is also a need for scientists to do more experiments 
and explore new types of probiotics. This will enable physicians to choose from a wider range 
of probiotics and develop a better combination to be used as adjunct treatments.
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